CYP2A13, CYP2A6, and the risk of lung adenocarcinoma in a Japanese population

Journal of Health Science

Volumn 51, Issue 6, 2005, Pages 658-666

  Kiyohara, Chikako ^a   Takayama, Koichi ^a   Nakanishi, Yoichi ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

CYP2A13; CYP2A6; Lung adenocarcinoma; Tobacco specific N nitrosamine

Indexed keywords

CYTOCHROME P450; CYTOCHROME P450 2A13; CYTOCHROME P450 2A6; DNA; UNCLASSIFIED DRUG;

ADULT; AGED; ALLELE; ARTICLE; BLOOD; CANCER PATIENT; CANCER RISK; CONFIDENCE INTERVAL; CONTROLLED STUDY; DEMOGRAPHY; DISEASE ASSOCIATION; DISEASE COURSE; GENE; GENE DELETION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; JAPAN; LIFESTYLE; LOGISTIC REGRESSION ANALYSIS; LUNG ADENOCARCINOMA; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; QUESTIONNAIRE; SMOKING;

ANIMALIA; NICOTIANA TABACUM;

EID: 28544447343     PISSN: 13449702     EISSN: 13475207     Source Type: Journal    
DOI: 10.1248/jhs.51.658     Document Type: Article

References (47)

1. Coleman, M. P., Esteve, J., Damiecki, P., Arslan, A. and Renard, H. (1993) Lung. In Trends in Cancer Incidence and Mortality, IARC Scientific Publications, No. 121, IARC, Lyon, pp. 311-342.
2. Law, M. R. (1990) Genetic predisposition to lung cancer. Br. J. Cancer, 61, 195-206.
3. Nakachi, K., Imai, K., Hayashi, S. and Kawajiri, K. (1993) Polymorphisms of the CYP1A1 and glutathione S-transferase genes associated with susceptibility to lung cancer in relation to cigarette dose in a Japanese population. Cancer Res., 53, 2994-2999.
4. Kiyohara, C. (2000) Genetic polymorphism of enzymes involved in xenobiotic metabolism and the risk of colorectal cancer. J. Epidemiol., 10, 349-360.
5. Smith, T. J., Guo, Z., Gonzalez, F. J., Guengerich, F. P., Stoner, G. D. and Yang, C. S. (1992) Metabolism of 4-(methylnitrosamino)-1-(3-pyridyl)-1- butanone in human lung and liver microsomes and cytochromes P-450 expressed in hepatoma cells. Cancer Res., 52, 1757-1763.
6. Staretz, M. E., Murphy, S. E., Patten, C. J., Nunes, M. G., Koehl, W., Amin, S., Koenig, L. A., Guengerich, F. P. and Hecht, S. S. (1997) Comparative metabolism of the tobacco-related carcinogens benzo[a]pyrene, 4-(methylnitrosamino)-1 -(3-pyridyl)-1-butanone, 4-(methylnitrosamino)-1-(3- pyridyl)-1-butanol, and N′-nitrosonornicotine in human hepatic microsomes. Drug Metab. Dispos., 25, 154-162.
7. Yoshimasu, K. and Kiyohara, C. (2003) Genetic influences on smoking behavior and nicotine dependence: a review. J. Epidemiol., 13, 183-192.
8. Fernandez-Salguero, P., Hoffman, S. M., Cholerton, S., Mohrenweiser, H., Raunio, H., Rautio, A., Pelkonen, O., Huang, J. D., Evans, W. E., Idle, J. R. and Gonzalez, F. J. (1995) A genetic polymorphism in coumarin 7-hydroxylation: sequence of the human CYP2A genes and identification of variant CYP2A6 alles. Am. J. Hum. Genet., 57, 651-660.
9. Hadidi, H., Zahlsen, K., Idle, J. R. and Cholerton, S. (1997) A single amino acid substitution (Leu160His) in cytochrome P450 CYP2A6 causes switching from 7-hydroxylation to 3-hydroxylation of coumarin. Food Chem. Toxicol., 35, 903-907.
10. Rautio, A., Gullsten, H. and Pelkonen, O. (1998) Expression and function of CYP2A genes in humans. Exp. Toxicol. Pathol., 50, 133-134.
11. Oscarson, M., McLellan, R. A., Gullsten, H., Agundez, J. A., Benitez, J., Rautio, A., Raunio, H., Pelkonen, O. and Ingelman-Sundberg, M. (1999) Identification and characterisation of novel polymorphisms in the CYP2A locus: implications for nicotine metabolism. FEBS Lett., 460, 321-327.
12. London, S. J., Idle, J. R., Daly, A. K. and Coetzee, G. A. (1999) Genetic variation of CYP2A6, smoking, and risk of cancer. Lancet, 353, 898-899.
13. Kamataki, T., Nunoya, K., Sakai, Y., Kushida, H. and Fujita, K. (1999) Genetic polymorphism of CYP2A6 in relation to cancer. Mutat. Res., 428, 125-130.
14. Miyamoto, M., Umetsu, Y., Dosaka-Akita, H., Sawamura, Y., Yokota, J., Kunitoh, H., Nemoto, N., Sato, K., Ariyoshi, N. and Kamataki, T. (1999) CYP2A6 gene deletion reduces susceptibility to lung cancer. Biochem. Biophys. Res. Commun., 261, 658-660.
15. Ariyoshi, N., Miyamoto, M., Umetsu, Y., Kunitoh, H., Dosaka-Akita, H., Sawamura, Y., Yokota, J., Nemoto, N., Sato, K. and Kamataki, T. (2002) Genetic polymorphism of CYP2A6 gene and tobacco-induced lung cancer risk in male smokers. Cancer Epidemiol. Biomarkers Prev., 11, 890-894.
16. Fujieda, M., Yamazaki, H., Saito, T., Kiyotani, K., Gyamfi, M. A., Sakurai, M., Dosaka-Akita, H., Sawamura, Y., Yokota, J., Kunitoh, H. and Kamataki, T. (2004) Evaluation of CYP2A6 genetic polymorphisms as determinants of smoking behavior and tobacco-related lung cancer risk in male Japanese smokers. Carcinogenesis, 25, 2451-2458.
17. Tan, W., Chen, G. F., Xing, D. Y., Song, C. Y., Kadlubar, F. F. and Lin, D. X. (2001) Frequency of CYP2A6 gene deletion and its relation to risk of lung and esophageal cancer in the Chinese population. Int. J. Cancer, 95, 96-101.
18. Su, T., Bao, Z., Zhang, Q. Y., Smith, T. J., Hong, J. Y. and Ding, X. (2000) Human cytochrome P450 CYP2A13: predominant expression in the respiratory tract and its high efficiency metabolic activation of a tobacco-specific carcinogen, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone. Cancer Res., 60, 5074-5079.
19. Zhang, X., Su, T., Zhang, Q. Y., Gu, J., Caggana, M., Li, H. and Ding, X. (2002) Genetic polymorphisms of the human CYP2A13 gene: identification of single-nucleotide polymorphisms and functional characterization of an Arg257Cys variant. J. Pharmacol. Exp. Ther., 302, 416-423.
20. Zhang, X., Chen, Y., Liu, Y., Ren, X., Zhang, Q. Y., Caggana, M. and Ding, X. (2003) Single nucleotide polymorphisms of the human cyp2a13 gene: evidence for a null allele. Drug Metab Dispos., 31, 1081-1085.
21. Fujieda, M., Yamazaki, H., Kiyotani, K., Muroi, A., Kunitoh, H., Dosaka-Akita, H., Sawamura, Y. and Kamataki, T. (2003) Eighteen novel polymorphisms of the CYP2A13 gene in Japanese. Drug Metab. Pharmacokinet., 18, 86-90.
22. Wang, H., Tan, W., Hao, B., Miao, X., Zhou, G., He, F. and Lin, D. (2003) Substantial reduction in risk of lung adenocarcinoma associated with genetic polymorphism in CYP2A13, the most active cytochrome P450 for the metabolic activation of tobacco-specific carcinogen NNK. Cancer Res., 63, 8057-8061.
23. Cauffiez, C., Lo-Guidice, J. M., Quaranta, S., Allorge, D., Chevalier, D., Cenee, S., Hamdan, R., Lhermitte, M., Lafitte, J. J., Libersa, C., Colombel, J. F., Stucker, I. and Broly, F. (2004) Genetic polymorphism of the human cytochrome CYP2A13 in a French population: implication in lung cancer susceptibility. Biochem. Biophys. Res. Commun., 317, 662-629.
24. Kiyohara, C., Nakanishi, Y., Inutsuka, S., Takayama, K., Hara, N., Motohiro, A., Tanaka, K., Kono, S. and Hirohata, T. (1998) The relationship between CYP1A1 aryl hydrocarbon hydroxylase activity and lung cancer in a Japanese population. Pharmacogenetics, 8, 315-323.
25. Ariyoshi, N., Sekine, H., Saito, K. and Kamataki, T. (2002) Characterization of a genotype previously designated as CYP2A6 D-type: CYP2A6*4B, another entire gene deletion allele of the CYP2A6 gene in Japanese. Pharmacogenetics, 12, 501-504.
26. Nunoya, K., Yokoi, T., Takahashi, Y., Kimura, K., Kinoshita, M. and Kamataki, T. (1999) Homologous unequal cross-over within the human CYP2A gene cluster as a mechanism for the deletion of the entire CYP2A6 gene associated with the poor metabolizer phenotype. J. Biochem. (Tokyo), 126, 402-407.
27. Nunoya, K., Yokoi, T., Kimura, K., Kainuma, T., Satoh, K., Kinoshita, M. and Kamataki, T. (1999) A new CYP2A6 gene deletion responsible for the in vivo polymorphic metabolism of (+)-cis-3,5-dim-ethyl-2-(3-pyridyl)thiazolidin-4-one hydrochloride in humans. J. Pharmacol Exp. Ther., 289, 437-442.
28. Levi, F., Franceschi, S., La Vecchia, C., Randimbison, L. and Te, V. C. (1997) Lung carcinoma trends by histologic type in Vaud and Neuchatel, Switzerland, 1974-1994. Cancer, 79, 906-914.
29. Wynder, E. L. and Muscat, J. E. (1995) The changing epidemiology of smoking and lung cancer histology. Environ. Health Perspect., 103, 143-148.
30. Patel, A. R. and Obrams, G. I. (1995) Adenocarcinoma of the lung. Cancer Epidemiol. Biomarkers Prev., 4, 175-180.
31. Travis, W. D., Lubin, J., Ries, L. and Devesa, S. (1996) United States lung carcinoma incidence trends: declining for most histologic types among males, increasing among females. Cancer, 77, 2464-2470.
32. Charloux, A., Quoix, E., Wolkove, N., Small, D., Pauli, G. and Kreisman, H. (1997) The increasing incidence of lung adenocarcinoma: reality or artefact? A review of the epidemiology of lung adenocarcinoma. Int. J. Epidemiol., 26, 14-23.
33. Sobue, T., Ajiki, W., Tsukuma, H., Oshima, A., Hanai, A. and Fujimoto, I. (1999) Trends of lung cancer incidence by histologic type: a population-based study in Osaka, Japan. Jpn. J. Cancer Res., 90, 6-15.
34. U.S. Surgeon General (1981) Health Consequence of smoking - The Changing Cigarette, DHHS (PHS) 81-50156, Rockville, Md.
35. Hecht, S. S., Morse, M. A., Amin, S., Stoner, G. D., Jordan, K. G., Choi, C. I. and Chung, F. L. (1989) Rapid single-dose model for lung tumor induction in A/J mice by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone and the effect of diet. Carcinogenesis, 10, 1901-1904.
36. Hoffmann, D., Rivenson, A., Murphy, S. E., Chung, F.-L., Amin, S. and Hecht, S. S. (1993) Cigarette smoking and adenocarcinoma of the lung: the relevance of nicotine-derived N-nitrosamines. J. Smoking Rel. Disord., 4, 165-190.
37. Hoffmann, D., Brunnemann, K. D., Prokopczyk, B. and Djordjevic, M. V. (1994) Tobacco-specific N-nitrosamines and Areca-derived N-nitrosamines: chemistry, biochemistry, carcinogenicity, and relevance to humans. J. Toxicol. Environ. Health, 41, 1-52.
38. IARC Monographs of the Evaluation of the Carcinogenic Risk of Chemicals to Humans (2002) Tobacco Smoke and Involuntary Smoking, IARC Scientifc Publication no. 83, IARC, Lyon.
39. Stock, S. L. (1980) Risks the passive smoker runs. Lancet, 2, 1082.
40. Ariyoshi, N., Takahashi, Y., Miyamoto, M., Umetsu, Y., Daigo, S., Tateishi, T., Kobayashi, S., Mizorogi, Y., Loriot, M. A., Stucker, I., Beaune, P., Kinoshita, M. and Kamataki, T. (2000) Structural characterization of a new variant of the CYP2A6 gene (CYP2A6*1B) apparently diagnosed as heterozygotes of CYP2A6*1A and CYP2A6*4C. Pharmacogenetics, 10, 687-693.
41. Oscarson, M., Gullsten, H., Rautio, A., Bernal, M. L., Sinues, B., Dahl, M. L., Stengard, J. H., Pelkonen, O., Raunio, H. and Ingelman-Sundberg, M. (1998) Genotyping of human cytochrome P450 2A6 (CYP2A6), a nicotine C-oxidase. FEBS Lett., 438, 201-205.
42. Oscarson, M., McLellan, R. A., Gullsten, H., Yue, Q. Y., Lang, M. A., Bernal, M. L., Sinues, B., Hirvonen, A., Raunio, H., Pelkonen, O. and Ingelman-Sundberg, M. (1999) Characterisation and PCR-based detection of a CYP2A6 gene deletion found at a high frequency in a Chinese population. FEBS Lett., 448, 105-110.
43. Raunio, H., Rautio, A., Gullsten, H. and Pelkonen, O. (2004) Polymorphisms of CYP2A6 and its practical consequences. Br. J. Clin. Pharmacol., 52, 357-363.
44. Vineis, P. and Martone, T. (1995) Genetic-environmental interactions and low-level exposure to carcinogens. Epidemiology, 6, 455-457.
45. Caporaso, N. E. (2002) Why have we failed to find the low penetrance genetic constituents of common cancers? Cancer Epidemiol. Biomarkers Prev., 11, 1544-1549.
46. Brennan, P. (2002) Gene-environment interaction and aetiology of cancer: what does it mean and how can we measure it? Carcinogenesis, 23, 381-387.
47. Goode, E. L., Ulrich, C. M. and Potter, J. D. (2002) Polymorphisms in DNA repair genes and associations with cancer risk. Cancer Epidemiol. Biomarkers Prev., 11, 1513-1530.